229 related articles for article (PubMed ID: 27666577)
1. Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging.
Miyashita M; Gonda K; Tada H; Watanabe M; Kitamura N; Kamei T; Sasano H; Ishida T; Ohuchi N
Cancer Med; 2016 Oct; 5(10):2813-2824. PubMed ID: 27666577
[TBL] [Abstract][Full Text] [Related]
2. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
3. Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer.
Sun JZ; Chen C; Jiang G; Tian WQ; Li Y; Sun SR
Int J Nanomedicine; 2014; 9():1339-46. PubMed ID: 24648732
[TBL] [Abstract][Full Text] [Related]
4. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
5. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
7. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
8. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.
Varga Z; Noske A; Ramach C; Padberg B; Moch H
BMC Cancer; 2013 Dec; 13():615. PubMed ID: 24377754
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
10. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
Giltnane JM; Molinaro A; Cheng H; Robinson A; Turbin D; Gelmon K; Huntsman D; Rimm DL
Arch Pathol Lab Med; 2008 Oct; 132(10):1635-47. PubMed ID: 18834223
[TBL] [Abstract][Full Text] [Related]
11. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
Perez EA; Baehner FL; Butler SM; Thompson EA; Dueck AC; Jamshidian F; Cherbavaz D; Yoshizawa C; Shak S; Kaufman PA; Davidson NE; Gralow J; Asmann YW; Ballman KV
Breast Cancer Res; 2015 Oct; 17(1):133. PubMed ID: 26429296
[TBL] [Abstract][Full Text] [Related]
12. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
[TBL] [Abstract][Full Text] [Related]
13. Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
Moatter T; Aban M; Iqbal W; Azam I; Pervaiz A; Siddiqui F; Murad F; Pervez S
Asian Pac J Cancer Prev; 2011; 12(11):3069-73. PubMed ID: 22393991
[TBL] [Abstract][Full Text] [Related]
14. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
15. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Gogas H; Kotoula V; Alexopoulou Z; Christodoulou C; Kostopoulos I; Bobos M; Raptou G; Charalambous E; Tsolaki E; Xanthakis I; Pentheroudakis G; Koutras A; Bafaloukos D; Papakostas P; Aravantinos G; Psyrri A; Petraki K; Kalogeras KT; Pectasides D; Fountzilas G
J Transl Med; 2016 May; 14(1):136. PubMed ID: 27184134
[TBL] [Abstract][Full Text] [Related]
16. Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2.
Tobin SJ; Wakefield DL; Jones V; Liu X; Schmolze D; Jovanović-Talisman T
Sci Rep; 2018 Oct; 8(1):15154. PubMed ID: 30310083
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
[TBL] [Abstract][Full Text] [Related]
18. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
19. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
